Amgen (NASDAQ:AMGN) Shares Sold Off Sen. Sheldon Whitehouse

Key Points

• Sen. Sheldon Whitehouse sold $1,001–$15,000 of Amgen shares on August 12, alongside several other stock sales and purchases disclosed in recent filings.
• Amgen reported stronger-than-expected quarterly results, with EPS of $6.29 and revenue of $10.05 billion, while raising its 2026 outlook. The company also declared a quarterly dividend of $2.52 per share, equivalent to a 2.3% yield.
• Amgen’s outlook is supported by positive Repatha and potential MariTide developments, but regulatory pressure on Tavneos in the U.K. and U.S. remains a significant risk. Analysts maintain a consensus “Hold” rating with an average price target of $381.68.

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on September 02nd, the Senator disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 12th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 8/13/2026.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 7/20/2026.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 6/30/2026.
• Sold $1,001 - $15,000 in shares of Crown Castle NYSE: CCI on 6/25/2026.
• Purchased $15,001 - $50,000 in shares of Coherent NYSE: COHR on 6/25/2026.
• Purchased $1,001 - $15,000 in shares of Micron Technology NASDAQ: MU on 6/25/2026.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 6/24/2026.

Amgen Stock Down 1.6%

Shares of Amgen stock opened at $437.23 on Friday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $447.03. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company's 50 day moving average is $397.39 and its 200 day moving average is $367.15. The company has a market cap of $236.38 billion, a price-to-earnings ratio of 27.17, a price-to-earnings-growth ratio of 3.20 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm's revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts anticipate that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Guggenheim boosted their target price on shares of Amgen from $343.00 to $388.00 and gave the company a "neutral" rating in a research report on Monday, August 10th. Argus upped their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a "buy" rating in a report on Wednesday, August 19th. Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Truist Financial raised their price target on Amgen from $340.00 to $362.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. Finally, Barclays upped their price objective on Amgen from $360.00 to $380.00 and gave the stock an "equal weight" rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $381.68.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company's stock.

Institutional Trading of Amgen

Several hedge funds have recently bought and sold shares of the stock. Anfield Capital Management LLC increased its holdings in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Tower View Wealth Management LLC boosted its position in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares during the last quarter. Manning & Napier Advisors LLC lifted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC bought a new position in shares of Amgen in the 1st quarter valued at about $37,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031. Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source